118 related articles for article (PubMed ID: 20846522)
1. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population.
Chiang CH; Huang CC; Chan WL; Chen JW; Leu HB
Clin Biochem; 2010 Dec; 43(18):1399-404. PubMed ID: 20846522
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.
Villanova N; Moscatiello S; Ramilli S; Bugianesi E; Magalotti D; Vanni E; Zoli M; Marchesini G
Hepatology; 2005 Aug; 42(2):473-80. PubMed ID: 15981216
[TBL] [Abstract][Full Text] [Related]
3. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.
Targher G; Bertolini L; Padovani R; Poli F; Scala L; Tessari R; Zenari L; Falezza G
Diabet Med; 2006 Apr; 23(4):403-9. PubMed ID: 16620269
[TBL] [Abstract][Full Text] [Related]
4. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease.
Targher G
J Hepatol; 2006 Dec; 45(6):879-81; author reply 881-2. PubMed ID: 17049665
[No Abstract] [Full Text] [Related]
5. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers.
Edens MA; Kuipers F; Stolk RP
Obes Rev; 2009 Jul; 10(4):412-9. PubMed ID: 19413701
[TBL] [Abstract][Full Text] [Related]
6. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
Fan JG
J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
[TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver, high sensitivity C reactive protein and insulin resistance].
Zhou WD; Yang YL; Che ZH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):565-70. PubMed ID: 18667766
[TBL] [Abstract][Full Text] [Related]
8. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
Jeppesen J; Hansen TW; Olsen MH; Rasmussen S; Ibsen H; Torp-Pedersen C; Hildebrandt PR; Madsbad S
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):594-8. PubMed ID: 18753952
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
Targher G
Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
[TBL] [Abstract][Full Text] [Related]
11. The role of non-alcoholic fatty liver disease in cardiovascular disease.
Perseghin G
Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
[TBL] [Abstract][Full Text] [Related]
12. [Taurine in the treatment of non-alcoholic fatty liver disease].
Zvenigorodskaia LA; Ovsiannikova ON; Noskova KK; Nilova TV; Elizarova EP
Eksp Klin Gastroenterol; 2010; (7):43-50. PubMed ID: 21033082
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease.
Das KS; Balakrishnan V; Mukherjee S; Vasudevan DM
Scand J Clin Lab Invest; 2008; 68(4):323-34. PubMed ID: 18609067
[TBL] [Abstract][Full Text] [Related]
14. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population.
Romero-Corral A; Sierra-Johnson J; Lopez-Jimenez F; Thomas RJ; Singh P; Hoffmann M; Okcay A; Korinek J; Wolk R; Somers VK
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5(7):418-25. PubMed ID: 18431365
[TBL] [Abstract][Full Text] [Related]
15. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass.
Picardi A; Vespasiani-Gentilucci U
Am J Gastroenterol; 2008 Dec; 103(12):3036-8. PubMed ID: 18853984
[TBL] [Abstract][Full Text] [Related]
16. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.
Ong JP; Pitts A; Younossi ZM
J Hepatol; 2008 Oct; 49(4):608-12. PubMed ID: 18682312
[TBL] [Abstract][Full Text] [Related]
17. [Non-alcoholic fatty liver disease as an atherosclerosis risk factor].
Roĭtberg GE; Sharkhun OO; Ushakova TI
Eksp Klin Gastroenterol; 2010; (7):20-4. PubMed ID: 21033079
[TBL] [Abstract][Full Text] [Related]
18. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis.
Manco M; Bedogni G; Marcellini M; Devito R; Ciampalini P; Sartorelli MR; Comparcola D; Piemonte F; Nobili V
Gut; 2008 Sep; 57(9):1283-7. PubMed ID: 18218674
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population.
Dassanayake AS; Kasturiratne A; Rajindrajith S; Kalubowila U; Chakrawarthi S; De Silva AP; Makaya M; Mizoue T; Kato N; Wickremasinghe AR; de Silva HJ
J Gastroenterol Hepatol; 2009 Jul; 24(7):1284-8. PubMed ID: 19476560
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
